Antiplatelet Drugs Market - Global Size, Share, Trend Analysis, Opportunity and Forecast Report, 2019-2029, Segmented By Drugs ; By Indication ; By Distribution Channel ; By Route of Administration ; By End Use ; By Region

Description

Global Antiplatelet Drugs Market Size Grows at CAGR of 5.32% During 2023-2029 to Reach USD 2.92 Billion by 2029

Global antiplatelet drugs market is flourishing due to the increasing prevalence of cardiovascular diseases, the growing aging population, advancements in drug development technologies, growing awareness about preventive healthcare, and a surge in demand for antiplatelet drugs for primary and secondary prevention of thrombotic events.

BlueWeave Consulting, a leading strategic consulting and market research firm, in its recent study, estimated the Global Antiplatelet Drugs Market size at USD 2.14 billion in 2022. During the forecast period between 2023 and 2029, the Global Antiplatelet Drugs Market size is to grow at a CAGR of 5.32% reaching a value of USD 2.92 billion by 2029. An increase in cardiovascular illnesses and associated problems worldwide are major factors behind the growth of the global market for antiplatelet medicines. To meet the demands of each patient specifically, pharmaceutical companies are concentrating on creating more sophisticated and individualized antiplatelet medicines. The market is witnessing a rapid increase in R&D activities, which could result in the development and launch of novel drug formulations. Antiplatelet medications are also being used more frequently in emerging economies, which is fueling market expansion. Also, improvements in patient compliance and new drug delivery techniques are adding to the market's upward trend.

Opportunity - Increasing Investments in Healthcare Infrastructure

As worldwide healthcare infrastructure experiences a significant upswing in investments, the Global Antiplatelet Drugs Market emerges as a lucrative sector for prospective investors. With a rising focus on enhancing medical facilities, there is a growing demand for advanced antiplatelet therapies. Seize the opportunity to contribute to this vital healthcare segment, ensuring access to innovative antiplatelet drugs that play a crucial role in preventing cardiovascular events. This market surge not only aligns with global health priorities but also presents a strategic investment avenue for those seeking sustainable returns in the flourishing landscape of healthcare advancements.

Impact of COVID-19 on Global Antiplatelet Drugs Market

The COVID-19 pandemic significantly impacted Global Antiplatelet Drugs Market, as healthcare systems worldwide shifted focus to combat the virus. During the peak of the pandemic, elective procedures were postponed, leading to reduced prescriptions and demand for antiplatelet drugs. Also, disruptions in the supply chain and manufacturing caused temporary shortages and price fluctuations. However, the market showed resilience with the increasing emphasis on telemedicine and outpatient care, ensuring continuous patient access to essential medications. As the pandemic abates, the Global Antiplatelet Drugs Market is expected to rebound, driven by the resumption of routine medical services and growing awareness of cardiovascular health.

Global Antiplatelet Drugs Market - By Indication

By indication, Global Antiplatelet Drugs Market is divided into Myocardial infarction, Percutaneous Coronary Interventions, and Arterial Thrombosis segments. Myocardial infarction is the largest segment in the Global Antiplatelet Drugs Market. The segment encompasses the treatment of heart attacks, which is a significant health concern worldwide. The demand for antiplatelet drugs to prevent blood clotting in patients suffering from myocardial infarction remains high due to the increasing prevalence of cardiovascular diseases. While percutaneous coronary interventions and arterial thrombosis are also important segments, myocardial infarction stands out as the most substantial contributor to the overall market revenue and growth, driven by the critical need for effective and life-saving treatments in this specific medical condition.

Competitive Landscape

Global Antiplatelet Drugs Market is fiercely competitive. Major companies in the market include Eli Lilly and Company, Pfizer Inc., GSK Group of Companies (U.S), Novartis AG, EnBiotix Inc., Johnson & Johnson Private Limited, Merck & Co., Inc., Alexion Pharmaceuticals, Inc., Melinta Therapeutics, LLC, Vertex Pharmaceuticals Incorporated, AnaSpec, AMP Biotech, Phoenix Biotechnology Inc., Novabiotics, and Ontores Biotechnologies Inc. These companies use various strategies, including increasing investments in their R&D activities, mergers, and acquisitions, joint ventures, collaborations, licensing agreements, and new product and service releases to further strengthen their position in Global Antiplatelet Drugs Market.

The in-depth analysis of the report provides information about growth potential, upcoming trends, and statistics of Global Antiplatelet Drugs Market. It also highlights the factors driving forecasts of total market size. The report promises to provide recent technology trends in Global Antiplatelet Drugs Market and industry insights to help decision-makers make sound strategic decisions. Furthermore, the report also analyzes the growth drivers, challenges, and competitive dynamics of the market.

Product Code: BWC231048

1. Research Framework

1.1. Research Objective
1.2. Drugs Overview
1.3. Market Segmentation

2. Executive Summary

3. Global Antiplatelet Drugs Market Insights

3.1. Industry Value Chain Analysis
3.2. DROC Analysis
- 3.2.1. Growth Drivers
  - 3.2.1.1. Increase in the prevalence of cardiac and hereditary diseases
  - 3.2.1.2. Growing demand for novel oral anticoagulants coupled with the aging population
- 3.2.2. Restraints
  - 3.2.2.1. Stringent regulatory policies
  - 3.2.2.2. High cost and side effects of antithrombotic drugs
- 3.2.3. Opportunities
  - 3.2.3.1. Increase in the number of research and development activities
  - 3.2.3.2. Increasing investment in healthcare infrastructure
- 3.2.4. Challenges
  - 3.2.4.1. Lack of healthcare infrastructure in developing economies
  - 3.2.4.2. Limitations in safety, efficacy, and tolerability of some antiplatelet drugs
3.3. Technological Advancements/Recent Developments
3.4. Regulatory Framework
3.5. Porter's Five Forces Analysis
- 3.5.1. Bargaining Power of Suppliers
- 3.5.2. Bargaining Power of Buyers
- 3.5.3. Threat of New Entrants
- 3.5.4. Threat of Substitutes
- 3.5.5. Intensity of Rivalry

4. Global Antiplatelet Drugs Market Overview

4.1. Market Size & Forecast, 2019-2029
- 4.1.1. By Value (USD Billion)
4.2. Market Share & Forecast
- 4.2.1. By Drugs
  - 4.2.1.1. Aspirin
  - 4.2.1.2. Clopidogrel
  - 4.2.1.3. Ticagrelor
  - 4.2.1.4. Prasugrel
  - 4.2.1.5. Others
- 4.2.2. By Indication
  - 4.2.2.1. Myocardial Infraction
  - 4.2.2.2. Percutaneous Coronary Interventions
  - 4.2.2.3. Arterial Thrombosis
  - 4.2.2.4. Others
- 4.2.3. By Distribution Channel
  - 4.2.3.1. Hospital Pharmacy
  - 4.2.3.2. Retail Pharmacy
  - 4.2.3.3. Online Pharmacy
  - 4.2.3.4. Others
- 4.2.4. By Route of Administration
  - 4.2.4.1. Oral
  - 4.2.4.2. Injectable
- 4.2.5. By End Use
  - 4.2.5.1. Hospitals
  - 4.2.5.2. Specialty Clinics
  - 4.2.5.3. Homecare
  - 4.2.5.4. Others
- 4.2.6. By Region
  - 4.2.6.1. North America
  - 4.2.6.2. Europe
  - 4.2.6.3. Asia Pacific (APAC)
  - 4.2.6.4. Latin America (LATAM)
  - 4.2.6.5. Middle East and Africa (MEA)

5. North America Antiplatelet Drugs Market

5.1. Market Size & Forecast, 2019-2029
- 5.1.1. By Value (USD Million)
5.2. Market Share & Forecast
- 5.2.1. By Drugs
- 5.2.2. By Indication
- 5.2.3. By Distribution Channel
- 5.2.4. By Route of Administration
- 5.2.5. By End Use
- 5.2.6. By Country
  - 5.2.6.1. United States
  - 5.2.6.1.1. By Drugs
  - 5.2.6.1.2. By Indication
  - 5.2.6.1.3. By Distribution Channel
  - 5.2.6.1.4. By Route of Administration
  - 5.2.6.1.5. By End Use
  - 5.2.6.2. Canada
  - 5.2.6.2.1. By Drugs
  - 5.2.6.2.2. By Indication
  - 5.2.6.2.3. By Distribution Channel
  - 5.2.6.2.4. By Route of Administration
  - 5.2.6.2.5. By End Use

6. Europe Antiplatelet Drugs Market

6.1. Market Size & Forecast, 2019-2029
- 6.1.1. By Value (USD Million)
6.2. Market Share & Forecast
- 6.2.1. By Drugs
- 6.2.2. By Indication
- 6.2.3. By Distribution Channel
- 6.2.4. By Route of Administration
- 6.2.5. By End Use
- 6.2.6. By Country
  - 6.2.6.1. Germany
  - 6.2.6.1.1. By Drugs
  - 6.2.6.1.2. By Indication
  - 6.2.6.1.3. By Distribution Channel
  - 6.2.6.1.4. By Route of Administration
  - 6.2.6.1.5. By End Use
  - 6.2.6.2. United Kingdom
  - 6.2.6.2.1. By Drugs
  - 6.2.6.2.2. By Indication
  - 6.2.6.2.3. By Distribution Channel
  - 6.2.6.2.4. By Route of Administration
  - 6.2.6.2.5. By End Use
  - 6.2.6.3. Italy
  - 6.2.6.3.1. By Drugs
  - 6.2.6.3.2. By Indication
  - 6.2.6.3.3. By Distribution Channel
  - 6.2.6.3.4. By Route of Administration
  - 6.2.6.3.5. By End Use
  - 6.2.6.4. France
  - 6.2.6.4.1. By Drugs
  - 6.2.6.4.2. By Indication
  - 6.2.6.4.3. By Distribution Channel
  - 6.2.6.4.4. By Route of Administration
  - 6.2.6.4.5. By End Use
  - 6.2.6.5. Spain
  - 6.2.6.5.1. By Drugs
  - 6.2.6.5.2. By Indication
  - 6.2.6.5.3. By Distribution Channel
  - 6.2.6.5.4. By Route of Administration
  - 6.2.6.5.5. By End Use
  - 6.2.6.6. Belgium
  - 6.2.6.6.1. By Drugs
  - 6.2.6.6.2. By Indication
  - 6.2.6.6.3. By Distribution Channel
  - 6.2.6.6.4. By Route of Administration
  - 6.2.6.6.5. By End Use
  - 6.2.6.7. Russia
  - 6.2.6.7.1. By Drugs
  - 6.2.6.7.2. By Indication
  - 6.2.6.7.3. By Distribution Channel
  - 6.2.6.7.4. By Route of Administration
  - 6.2.6.7.5. By End Use
  - 6.2.6.8. The Netherlands
  - 6.2.6.8.1. By Drugs
  - 6.2.6.8.2. By Indication
  - 6.2.6.8.3. By Distribution Channel
  - 6.2.6.8.4. By Route of Administration
  - 6.2.6.8.5. By End Use
  - 6.2.6.9. Rest of Europe
  - 6.2.6.9.1. By Drugs
  - 6.2.6.9.2. By Indication
  - 6.2.6.9.3. By Distribution Channel
  - 6.2.6.9.4. By Route of Administration
  - 6.2.6.9.5. By End Use

7. Asia Pacific Antiplatelet Drugs Market

7.1. Market Size & Forecast, 2019-2029
- 7.1.1. By Value (USD Million)
7.2. Market Share & Forecast
- 7.2.1. By Drugs
- 7.2.2. By Indication
- 7.2.3. By Distribution Channel
- 7.2.4. By Route of Administration
- 7.2.5. By End Use
- 7.2.6. By Country
  - 7.2.6.1. China
  - 7.2.6.1.1. By Drugs
  - 7.2.6.1.2. By Indication
  - 7.2.6.1.3. By Distribution Channel
  - 7.2.6.1.4. By Route of Administration
  - 7.2.6.1.5. By End Use
  - 7.2.6.2. India
  - 7.2.6.2.1. By Drugs
  - 7.2.6.2.2. By Indication
  - 7.2.6.2.3. By Distribution Channel
  - 7.2.6.2.4. By Route of Administration
  - 7.2.6.2.5. By End Use
  - 7.2.6.3. Japan
  - 7.2.6.3.1. By Drugs
  - 7.2.6.3.2. By Indication
  - 7.2.6.3.3. By Distribution Channel
  - 7.2.6.3.4. By Route of Administration
  - 7.2.6.3.5. By End Use
  - 7.2.6.4. South Korea
  - 7.2.6.4.1. By Drugs
  - 7.2.6.4.2. By Indication
  - 7.2.6.4.3. By Distribution Channel
  - 7.2.6.4.4. By Route of Administration
  - 7.2.6.4.5. By End Use
  - 7.2.6.5. Australia & New Zealand
  - 7.2.6.5.1. By Drugs
  - 7.2.6.5.2. By Indication
  - 7.2.6.5.3. By Distribution Channel
  - 7.2.6.5.4. By Route of Administration
  - 7.2.6.5.5. By End Use
  - 7.2.6.6. Indonesia
  - 7.2.6.6.1. By Drugs
  - 7.2.6.6.2. By Indication
  - 7.2.6.6.3. By Distribution Channel
  - 7.2.6.6.4. By Route of Administration
  - 7.2.6.6.5. By End Use
  - 7.2.6.7. Malaysia
  - 7.2.6.7.1. By Drugs
  - 7.2.6.7.2. By Indication
  - 7.2.6.7.3. By Distribution Channel
  - 7.2.6.7.4. By Route of Administration
  - 7.2.6.7.5. By End Use
  - 7.2.6.8. Singapore
  - 7.2.6.8.1. By Drugs
  - 7.2.6.8.2. By Indication
  - 7.2.6.8.3. By Distribution Channel
  - 7.2.6.8.4. By Route of Administration
  - 7.2.6.8.5. By End Use
  - 7.2.6.9. Vietnam
  - 7.2.6.9.1. By Drugs
  - 7.2.6.9.2. By Indication
  - 7.2.6.9.3. By Distribution Channel
  - 7.2.6.9.4. By Route of Administration
  - 7.2.6.9.5. By End Use
  - 7.2.6.10. Rest of APAC
  - 7.2.6.10.1. By Drugs
  - 7.2.6.10.2. By Indication
  - 7.2.6.10.3. By Distribution Channel
  - 7.2.6.10.4. By Route of Administration
  - 7.2.6.10.5. By End Use

8. Latin America Antiplatelet Drugs Market

8.1. Market Size & Forecast, 2019-2029
- 8.1.1. By Value (USD Million)
8.2. Market Share & Forecast
- 8.2.1. By Drugs
- 8.2.2. By Indication
- 8.2.3. By Distribution Channel
- 8.2.4. By Route of Administration
- 8.2.5. By End Use
- 8.2.6. By Country
  - 8.2.6.1. Brazil
  - 8.2.6.1.1. By Drugs
  - 8.2.6.1.2. By Indication
  - 8.2.6.1.3. By Distribution Channel
  - 8.2.6.1.4. By Route of Administration
  - 8.2.6.1.5. By End Use
  - 8.2.6.2. Mexico
  - 8.2.6.2.1. By Drugs
  - 8.2.6.2.2. By Indication
  - 8.2.6.2.3. By Distribution Channel
  - 8.2.6.2.4. By Route of Administration
  - 8.2.6.2.5. By End Use
  - 8.2.6.3. Argentina
  - 8.2.6.3.1. By Drugs
  - 8.2.6.3.2. By Indication
  - 8.2.6.3.3. By Distribution Channel
  - 8.2.6.3.4. By Route of Administration
  - 8.2.6.3.5. By End Use
  - 8.2.6.4. Peru
  - 8.2.6.4.1. By Drugs
  - 8.2.6.4.2. By Indication
  - 8.2.6.4.3. By Distribution Channel
  - 8.2.6.4.4. By Route of Administration
  - 8.2.6.4.5. By End Use
  - 8.2.6.5. Rest of LATAM
  - 8.2.6.5.1. By Drugs
  - 8.2.6.5.2. By Indication
  - 8.2.6.5.3. By Distribution Channel
  - 8.2.6.5.4. By Route of Administration
  - 8.2.6.5.5. By End Use

9. Middle East and Africa Antiplatelet Drugs Market

9.1. Market Size & Forecast, 2019-2029
- 9.1.1. By Value (USD Million)
9.2. Market Share & Forecast
- 9.2.1. By Drugs
- 9.2.2. By Indication
- 9.2.3. By Distribution Channel
- 9.2.4. By Route of Administration
- 9.2.5. By End Use
- 9.2.6. By Country
  - 9.2.6.1. Saudi Arabia
  - 9.2.6.1.1. By Drugs
  - 9.2.6.1.2. By Indication
  - 9.2.6.1.3. By Distribution Channel
  - 9.2.6.1.4. By Route of Administration
  - 9.2.6.1.5. By End Use
  - 9.2.6.2. UAE
  - 9.2.6.2.1. By Drugs
  - 9.2.6.2.2. By Indication
  - 9.2.6.2.3. By Distribution Channel
  - 9.2.6.2.4. By Route of Administration
  - 9.2.6.2.5. By End Use
  - 9.2.6.3. Qatar
  - 9.2.6.3.1. By Drugs
  - 9.2.6.3.2. By Indication
  - 9.2.6.3.3. By Distribution Channel
  - 9.2.6.3.4. By Route of Administration
  - 9.2.6.3.5. By End Use
  - 9.2.6.4. Kuwait
  - 9.2.6.4.1. By Drugs
  - 9.2.6.4.2. By Indication
  - 9.2.6.4.3. By Distribution Channel
  - 9.2.6.4.4. By Route of Administration
  - 9.2.6.4.5. By End Use
  - 9.2.6.5. South Africa
  - 9.2.6.5.1. By Drugs
  - 9.2.6.5.2. By Indication
  - 9.2.6.5.3. By Distribution Channel
  - 9.2.6.5.4. By Route of Administration
  - 9.2.6.5.5. By End Use
  - 9.2.6.6. Nigeria
  - 9.2.6.6.1. By Drugs
  - 9.2.6.6.2. By Indication
  - 9.2.6.6.3. By Distribution Channel
  - 9.2.6.6.4. By Route of Administration
  - 9.2.6.6.5. By End Use
  - 9.2.6.7. Algeria
  - 9.2.6.7.1. By Drugs
  - 9.2.6.7.2. By Indication
  - 9.2.6.7.3. By Distribution Channel
  - 9.2.6.7.4. By Route of Administration
  - 9.2.6.7.5. By End Use
  - 9.2.6.8. Rest of MEA
  - 9.2.6.8.1. By Drugs
  - 9.2.6.8.2. By Indication
  - 9.2.6.8.3. By Distribution Channel
  - 9.2.6.8.4. By Route of Administration
  - 9.2.6.8.5. By End Use

10. Competitive Landscape

10.1. List of Key Players and Their Offerings
10.2. Global Antiplatelet Drugs Company Market Share Analysis, 2022
10.3. Competitive Benchmarking, By Operating Parameters
10.4. Key Strategic Developments (Mergers, Acquisitions, Partnerships, etc.)

11. Impact of COVID-19 on Global Antiplatelet Drugs Market

12. Company Profile (Company Overview, Financial Matrix, Competitive Landscape, Key Personnel, Key Competitors, Contact Address, Strategic Outlook, SWOT Analysis)

12.1. Eli Lilly and Company
12.2. Pfizer Inc.
12.3. GSK Group of Companies (U.S)
12.4. Novartis AG
12.5. EnBiotix Inc.
12.6. Johnson & Johnson Private Limited
12.7. Merck & Co., Inc.
12.8. Alexion Pharmaceuticals, Inc.
12.9. Melinta Therapeutics, LLC
12.10. Vertex Pharmaceuticals Incorporated
12.11. AnaSpec
12.12. AMP Biotech
12.13. Phoenix Biotechnology Inc.
12.14. Novabiotics
12.15. Ontores Biotechnologies Inc.
12.16. Other Prominent Players

13. Key Strategic Recommendations

14. Research Methodology

14.1. Qualitative Research
- 14.1.1. Primary & Secondary Research
14.2. Quantitative Research
14.3. Market Breakdown & Data Triangulation
- 14.3.1. Secondary Research
- 14.3.2. Primary Research
14.4. Breakdown of Primary Research Respondents, By Region
14.5. Assumptions & Limitations